Skip to main content
. 2018 Apr 1;17(3):e12759. doi: 10.1111/acel.12759

Figure 1.

Figure 1

Antileukotriene therapy ameliorates behavioral deficits in P301S transgenic mice. Starting at 3 months of age, wild‐type (WT) and P301S mice were randomized to receive zileuton or vehicle until 10 months of age and then assessed in the Y‐maze and the Morris water maze. (a) Total number of arm entries for WT, WT‐zileuton, P301S, and P301S‐zileuton mice. (b) Percentage of alterations for the same four groups of mice (*p < .001). (c) Morris water maze training phase. Latency to initial platform crossing for WT, WT‐zileuton, P301S, and P301S‐zileuton. (d) Average swim speed for the four groups of mice. (e) Probe phase. Total number of entries to the target platform zone for each of the four groups of mice (WT, WT‐zileuton, P301S, and P301S‐zileuton mice) (*p < .001). (f) Latency to initial platform crossing for the same four groups of mice (*p < .001). (n = 10 per group). Results are mean ± SEM